599-79-1O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1ONCEXYHBECQHGNR-UHFFFAOYSA-NSulfasalazine (salicylazosulfapyridine) can cause cancer according to The National Toxicology Program. It can cause male reproductive toxicity according to state or federal government labeling requirements.
599-79-1DTXSID0021256CHEMBL100848、CHEMBL242373CHEBI:9334Pharmaceuticals -> Used in Switzerland
Pharmaceuticals -> Antibiotics
Pharmaceuticals -> Analgesics and anti-inflammatories
Pharmaceuticals -> Listed in ZINC15
2.65
0.6
203.9 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID0021256]
199.36 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
200.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
199.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Sulfasalazine
46.6
197.2
Maintenance therapy dosage for adults is 2 g daily.
Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 2000 mg/day, Lowest Therapeutic Dose (LTD): 25.0 mg/kg-day, and Screening Dose: 0.008 mg/kg-day.
10-Feb-21
The mode of action of sulfasalazine or its metabolites, 5-aminosalicylic acid and sulfapyridine, is still under investigation but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and <i>in vitro</i> models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver, and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of sulfasalazine, sulfapyridine, and 5-aminosalicylic acid have indicated that the major therapeutic action may reside in the 5-aminosalicylic acid moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown.
Although the exact mechanism of action of sulfasalazine is not fully understood, it is thought to be mediated through the inhibition of various inflammatory molecules. Research have found that sulfasalazine and its metabolites, mesalazine and sulfapyridine, can inhibit leukotrienes and prostaglandins by blocking the cyclo-oxygenase and lipoxygenase pathway. Specific enzymes that were investigated include phospholipase A2, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX2), and arachidonate 5-lipoxygenase. Inhibitory activities on other non-arachidonic acid derivatives have also been observed, including PPAR gamma, NF-Kb, and IkappaB kinases alpha and beta.
The observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours.In fast acetylators, the mean plasma half-life of sulfapyridine is 10.4 hours while in slow acetylators, it is 14.8 hours.Due to low plasma levels produced by 5-aminosalicylic acid after oral administration, reliable estimates of plasma half-life are not possible.
In the intestine, sulfasalazine is metabolized by intestinal bacteria to sulfapyridine and 5-aminosalicylic acid. Of the two species, sulfapyridine is relatively well absorbed from the intestine and highly metabolized, while 5-aminosalicylic acid is much less well absorbed.Approximately 15% of a dose of sulfasalazine is absorbed as the parent drug and is metabolized to some extent in the liver to the same two species.Sulfapyridine can also be metabolized to 5-hydroxysulfapyridine and N-acetyl-5-hydroxy sulfapyridine. 5-aminosalicylic acid is primarily metabolized in both the liver and intestine to N-acetyl-5 aminosalicylic acid via a non-acetylation phenotype-dependent route.
Following oral administration of 1 g of sulfasalazine to 9 healthy males, less than 15% of a dose of sulfasalazine is absorbed as the parent drug. Detectable serum concentrations of sulfasalazine have been found in healthy subjects within 90 minutes after ingestion. Maximum concentrations of sulfasalazine occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 μg/mL) occurring at 6 hours.
Absorbed sulfapyridine and 5-aminosalicylic acid and their metabolites are primarily eliminated in the urine either as free metabolites or as glucuronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-aminosalicylic acid and acetyl-5-aminosalicylic acid in the feces.
Following intravenous injection, the calculated volume of distribution for sulfasalazine was 7.5 ± 1.6 L.
The calculated clearance of sulfasalazine following intravenous administration was 1 L/hr. Renal clearance was estimated to account for 37% of total clearance.
DescriptionSulfasalazine (brand name Azulfidine in the U.S., Salazopyrin and Sulazine in Europe and Hong Kong) was developed in the 1950s specifically to treat rheumatoid arthritis. It was believed at the time that bacterial infections were the cause of rheumatoid arthritis. Sulfasalazine is a sulfa drug, (a derivative of mesalazine) and is formed by combining sulfa pyridine and salicylate with an azo bond. It may be abbreviated SSZ.
UsesAnti-inflammatory (gastrointestinal). Has been used in granulomatous colitis.
Usesanticolitis and Crohn's disease
UsesSulfasalazine is an anti-inflammatory (gastrointestinal). Sulfasalazine has been used in granulomatous colitis.
UsesSulfasalazine is a prodrug of the anti-inflammatory agent 5-aminosalicylic acid that is covalently linked to the antibiotic sulfapyridine by an azo bond. This bond is rapidly cleaved by bacteria in the terminal ileum and colon, thus releasing the active anti-inflammatory component. It has long been used in treatment of inflammatory bowel disease and rheumatoid arthritis because of its ability to induce T lymphocyte apoptosis, modulate inflammatory mediators from both cyclooxygenase/5-lipoxygenase pathways and NF-κB signaling pathways, attenuate transcription of proinflammatory cytokines, and activate PPARγ.[Cayman Chemical]
UsesAn inhibitor of of GSH-H-transferase and NF-kB activation and an apoptosis inducer
General DescriptionOdorless yellow or brownish-yellow to orange powder. Tasteless.
General DescriptionSulfasalazine (Azufidine) is an azo prodrug that is reducedby the bacterium present in the lower intestine to its activemetabolites, sulfapyridine and 5-aminosalicylic acid (5-ASA or mesalamine). It has been used for the treatment ofRA or ankylosing spondylitis, and inflammatory bowel diseases(IBDs) such as ulcerative colitis and Crohn disease.It is generally agreed that the therapeutic effects of sulfasalazinein treating IBDs are due mainly through its activemetabolite, 5-ASA. 5-ASA is believed to work, via similarmechanisms of action to the salicylates discussed earlier, byblocking prostaglandin synthesis in the lower intestine. On the other hand, because 5-ASA is completelyionized and very little of this metabolite can enter into systemiccirculation, the antirheumatic effects of sulfasalazinehave been attributed to its other active metabolite, sulfapyridine. In a more recent study, sulfasalazine and sulfapyridinewere found to inhibit 5-aminoimidazole-4-carboxamideribonucleotide transformylase, an enzyme involved in denovo purine biosynthesis. Sulfasalazine also inhibits neutrophilfunction, reduces immunoglobulin levels, and interfereswith T-cell function via suppression of NF-κB activation. Furthermore, like methotrexate, sulfasalazine hasalso been shown to inhibit osteoclastogenesis, thereby preventingbone erosion in arthritic patients.It should be pointed out that approximately one third of thepatients treated long term with sulfasalazine discontinued thedrug because of dose-related adverse effects including nausea,dyspepsia, vomiting, headache, rash, gastric distress, especiallyin patients on a daily dosage of greater than 4 g (or aserum sulfapyridine levels above 50 mg/mL).
DefinitionChEBI: An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.